JP2010538020A5 - - Google Patents

Download PDF

Info

Publication number
JP2010538020A5
JP2010538020A5 JP2010523239A JP2010523239A JP2010538020A5 JP 2010538020 A5 JP2010538020 A5 JP 2010538020A5 JP 2010523239 A JP2010523239 A JP 2010523239A JP 2010523239 A JP2010523239 A JP 2010523239A JP 2010538020 A5 JP2010538020 A5 JP 2010538020A5
Authority
JP
Japan
Prior art keywords
protein
crystallin
fragment
composition
angiogenic fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010523239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010538020A (ja
JP5685773B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2008/001319 external-priority patent/WO2009029991A1/en
Publication of JP2010538020A publication Critical patent/JP2010538020A/ja
Publication of JP2010538020A5 publication Critical patent/JP2010538020A5/ja
Application granted granted Critical
Publication of JP5685773B2 publication Critical patent/JP5685773B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010523239A 2007-09-07 2008-09-05 血管新生および創傷治癒活性がある薬剤 Expired - Fee Related JP5685773B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2007904857A AU2007904857A0 (en) 2007-09-07 Agents with angiogenic and wound healing activity
AU2007904857 2007-09-07
PCT/AU2008/001319 WO2009029991A1 (en) 2007-09-07 2008-09-05 Agents with angiogenic and wound healing activity

Publications (3)

Publication Number Publication Date
JP2010538020A JP2010538020A (ja) 2010-12-09
JP2010538020A5 true JP2010538020A5 (enExample) 2011-10-20
JP5685773B2 JP5685773B2 (ja) 2015-03-18

Family

ID=40428369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010523239A Expired - Fee Related JP5685773B2 (ja) 2007-09-07 2008-09-05 血管新生および創傷治癒活性がある薬剤

Country Status (6)

Country Link
US (1) US8404644B2 (enExample)
EP (2) EP2407175A1 (enExample)
JP (1) JP5685773B2 (enExample)
AU (1) AU2008295449A1 (enExample)
NZ (1) NZ583803A (enExample)
WO (1) WO2009029991A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404644B2 (en) * 2007-09-07 2013-03-26 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
JP2013513622A (ja) * 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ 白内障及び老眼を阻害する方法
CA2823505A1 (en) * 2011-01-26 2012-08-02 Megmilk Snow Brand Co., Ltd. Agent for improving peripheral sensitivity of skin
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
JP2014005254A (ja) * 2012-06-26 2014-01-16 Bfsr:Kk 熱傷由来全身性炎症反応症候群の予防外用薬
CN105209033B (zh) 2013-03-14 2018-09-18 马萨诸塞大学 抑制白内障和老花眼的方法
KR20170040648A (ko) * 2015-10-05 2017-04-13 차의과학대학교 산학협력단 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물
CN108348494A (zh) 2015-11-13 2018-07-31 马萨诸塞大学 用于抑制白内障和老花眼的含peg的双官能分子
US20220088265A1 (en) * 2019-02-08 2022-03-24 Manmeet Kaur Biomaterials and methods related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187482A1 (en) * 1995-10-13 1997-04-14 Eri Inoue Pharmaceutical composition
WO1999051634A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-3
WO1999051738A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-4
CA2342886A1 (en) 1998-10-15 2000-04-20 E.I. Du Pont De Nemours And Company Polymers, containing a fluorocyclobutyl ring and their preparation
WO2004005883A2 (en) * 2002-07-02 2004-01-15 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
JP3783200B2 (ja) * 2000-08-24 2006-06-07 株式会社加美乃素本舗 血管新生剤
US20030215424A1 (en) 2002-05-15 2003-11-20 Seul Kyung Hwan Method of modulating angiogenesis
US7263214B2 (en) 2002-05-15 2007-08-28 Ge Medical Systems Global Technology Company Llc Computer aided diagnosis from multiple energy images
WO2004096277A1 (ja) * 2003-05-01 2004-11-11 Kyoto University 眼内血管新生疾患の予防又は治療剤
WO2005004894A2 (en) * 2003-05-12 2005-01-20 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
CA2573720A1 (en) * 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
EP2662088A3 (en) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
US7897581B2 (en) 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
EP1978988A4 (en) 2006-01-13 2009-11-04 Univ New York State Res Found PEPTIDE-BASED REGULATION OF GAP-JUNCTIONS
WO2008005021A1 (en) * 2006-06-30 2008-01-10 The Johns Hopkins University Use of crystallin for the modulation of angiogenesis
JP5960944B2 (ja) 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
JP2010512403A (ja) 2006-12-11 2010-04-22 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 炎症の治療法としてのαＢクリスタリン
WO2009012224A2 (en) 2007-07-13 2009-01-22 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
US8404644B2 (en) * 2007-09-07 2013-03-26 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity

Similar Documents

Publication Publication Date Title
JP2014530220A5 (enExample)
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
JP2010222367A5 (enExample)
ATE516285T1 (de) Dihydropyridinonderivate
JP2013522184A5 (enExample)
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
AR064944A1 (es) Molecula que comprende un fragmento de anticuerpo que enlaza especificamente el peptido a(beta) humano entre las posiciones de aminoacido 13 a 28, composicion que comprende dicha molecula y su uso para la preparacion de un medicamento
JP2013155188A5 (enExample)
NO20084187L (no) Medikamenter og proteiner
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
JP2019533722A5 (enExample)
CO6640218A2 (es) Heterociclilbencillporazoles sustituidos y uso de los mismos
JP2014530873A5 (enExample)
DOP2015000028A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
NZ583803A (en) Agents with angiogenic and wound healing activity
PH12014501579A1 (en) Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers
BR0009186A (pt) Sais de ácidos asiático e madecássico adequados para preparação de composições farmacêuticas e cosméticas
BRPI0913839A2 (pt) composição farmacêutica com glicosaminoglicanos e uso da mesma no tratamento de úlceras crônicas
SV2010003578A (es) Oxazolidinonas para el tratamiento y profilaxis de la insuficiencia cardiaca
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
ES2421407T3 (es) Agente y composición para la curación de heridas
JP2011012060A5 (enExample)
AR077427A1 (es) Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st